Sulfathiazole

Summary

Sulfathiazole (CHEMBL437) is an approved small-molecule antiinfective agent (ATC D06BA02); indicated across 1 condition including bacterial infectious disease.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• ATC class: D06BA02 (+1 more)
• Indications: 1 condition
• Chemistry: 255.3 Da · C9H9N3O2S2

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL437
Name	Sulfathiazole
Type	Small molecule
Max phase	4
FDA approved	yes
PubChem CID	5340
ChEBI	CHEBI:9337
ATC	D06BA02, J01EB07
Molecular formula	C9H9N3O2S2
Molecular weight	255.3
InChIKey	JNMRHUJNCSQMMB-UHFFFAOYSA-N

SMILES: C1=CC(=CC=C1N)S(=O)(=O)NC2=NC=CS2

IUPAC name: 4-amino-N-(1,3-thiazol-2-yl)benzenesulfonamide

ChEBI definition: A 1,3-thiazole compound having a 4-aminobenzenesulfonamido group at the 2-position.

Pharmacological roles (ChEBI): antiinfective agent, EC 2.5.1.15 (dihydropteroate synthase) inhibitor, drug allergen.

Other ChEBI roles (chemical / environmental): environmental contaminant, xenobiotic.

Also known as: NSC-31812, NSC-683531, Sulfathiazol, Sulfathiazole, Sulfathiazole (triple sulfa), Sulfathiazole component of gyne-sulf, Sulfathiazole component of sultrin, Sulfathiazole component of trysul, Sulfathiazole component of vagilia, Sulfatiazol, Thiazamide, Triple sulfa (sulfathiazole)

Parent form; salt/anhydrous children: CHEMBL2107243, CHEMBL3780934

Patent coverage: 2,619 distinct patent families (7,148 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Broader ChEMBL bioactivity targets: 12 (assay-derived). Sample: Tyrosyl-DNA phosphodiesterase 1, Transcriptional activator protein LasR, Protein arginine N-methyltransferase 6, Lysine-specific demethylase 4E, Prelamin-A/C, Sodium-dependent serotonin transporter, Alpha-1A adrenergic receptor, Endothelin-1 receptor, Cytochrome P450 2C9, Aldehyde dehydrogenase 1A1.

Bioactivity

ChEMBL activities: 7 potent at pChembl ≥ 5 of 13 total. Top 30 by potency (10 = 0.1 nM, 6 = 1 µM):

Target	pChembl	Type	Value	Unit	Activity ID
TDP1	5.65	Potency	2239	nM	CHEMBL_ACT_3931955
P0AC13	5.6	IC50	2500	nM	CHEMBL_ACT_743504
SLC6A4	5.58	AC50	2600	nM	CHEMBL_ACT_25150985
ADRA1A	5.29	AC50	5100	nM	CHEMBL_ACT_25138303
P25084	5.05	IC50	9000	nM	CHEMBL_ACT_18731676
P25084	5.05	IC50	9000	nM	CHEMBL_ACT_26037555
CYP2C9	5	Potency	10000	nM	CHEMBL_ACT_5033400

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

1 indication (1 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
bacterial infectious disease	4	MONDO:0005113	EFO:0000771

Clinical trials

Total trials: 0.

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).